Safety & Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19

This is a prospective, open-label, randomized, controlled clinical investigation designed to evaluate the safety and effectiveness of the Exthera Medical Seraph 100 Microbind Affinity Blood Filter in the treatment of patients with confirmed SARS-CoV-2 infection.

The clinical investigation will be conducted at 3 centers in Germany and at 2 centers in Spain. Subjects will be randomized to the treatment group (Seraph 100 + standard of care) versus control group (standard of care only).

Subjects will be followed for 28 days. For viral quantification, study-related serum samples are done immediately before the initial treatment with Seraph 100 starts in the treatment group or immediately after randomization into the control group. Additionally, serum sampling at timepoint 12 hours is applicable for both treatment and control group.

Inclusion criteria

• Subjects with confirmed SARS-CoV-2 infection
• Be ≥ 18 years old and ≤90 years old
• Acute respiratory distress syndrome assessed by a modified Sequential Organ Failure Assessment score of at least 2 points
• At least one additional organ dysfunction assessed by a modified Sequential Organ Failure Assessment score of at least 1 point
• Written or electronic consent of the subjects who are legally competent and have the capacity to give consent

Exclusion criteria

• Subject is currently participating in another clinical investigation
• Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
• Presence of comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
• Have Child-Pugh Class C cirrhosis
• Have platelet count <30.000/uL
• Contraindications for heparin sodium for injection
• Subjects demonstrating any contraindication for this treatment as described in the IFU
• Subjects with known allergy of polyethylene and copolyester
• Subjects with hospital-acquired SARS-CoV-2 infections
• Subject is held in an institution by court or official order
• Subject is dependent on the sponsor or investigator so that consent can no longer be considered voluntary